Suchen
Gilead Sciences Inc
GILDZur Watchlist hinzufügen
125.160USD
+0.110+0.09%
Handelsschluss 06/24, 16:00（ET）Kurse um 15 Minuten verzögert
155.39BMarktkapitalisierung
16.88KGV TTM
mehr Informationen über Gilead Sciences Inc Unternehmen
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
Gilead Sciences Inc Informationen
BörsenkürzelGILD
Name des UnternehmensGilead Sciences Inc
IPO-datumJan 22, 1992
CEOO'Day (Daniel P)
Anzahl der mitarbeiter17600
WertpapierartOrdinary Share
GeschäftsjahresendeJan 22
Addresse333 Lakeside Dr
StadtFOSTER CITY
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94404-1147
Telefon16505743000
Websitehttps://www.gilead.com/
BörsenkürzelGILD
IPO-datumJan 22, 1992
CEOO'Day (Daniel P)
Führungskräfte von Gilead Sciences Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
124.23K
-1.24%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
27.20K
+4.21%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
12.89K
+8.89%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel P. O'Day
Mr. Daniel P. O'Day
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Sandra J. Horning, M.D.
Dr. Sandra J. Horning, M.D.
Independent Director
Independent Director
--
--
Mr. Javier J. Rodriguez
Mr. Javier J. Rodriguez
Independent Director
Independent Director
--
--
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
124.23K
-1.24%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
27.20K
+4.21%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
12.89K
+8.89%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Gilead Sciences Inc?
Die fünf größten Anteilseigner von Gilead Sciences Inc sind: Ms. Johanna Mercier
Wie viele Institutionen halten Anteile an Gilead Sciences Inc (GILD)?
Mit Stand vom 2026Q1 halten 3702 Institutionen Anteile an Gilead Sciences Inc, mit einem Gesamtmarktwert von etwa 1.14B, was 92.19% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2548741.00 gestiegen.
Was ist die größte Einnahmequelle von Gilead Sciences Inc?
Am 2026Q1 erzielte das Geschäft mit Biktarvy für Gilead Sciences Inc den höchsten Umsatz in Höhe von 14.33B, was 48.68% des Gesamtumsatzes entspricht.
